OUR CROP-Seq (Perturb-Seq) TECHNOLOGY PLATFORM ENABLING CRISPR SCREENS LINKED TO SINGLE-CELL RNA SEQUENCING
Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable single-cell CRISPR screens for complex cellular phenotypes.
CROP-Seq & CRISPR perturbation screening
CRISPR screening has revolutionized the unbiased annotation of gene function, but most screens done so far have been confined to rather simplistic read-outs (usually life/death of the target cells). Combining pooled CRISPR perturbation with single-cell RNA sequencing allows researchers to assess much more complex phenotypes, thus effectively broadening the scope of these single-cell CRISPR screens. At Myllia, we use the CROP-Seq (Perturb-Seq) technology to perturb cells with CRISPR/Cas9 and profile transcriptional outcomes at scale by RNA sequencing at single-cell resolution. Importantly, our technology is applicable across a wide range of cell types including primary immune cells. The latter include primary human T cells or monocyte-derived cells isolated from PBMCs which are of great interest for the discovery of novel targets in immuno-oncology.
CROP-Seq & CRISPR perturbation screening
CRISPR screening has revolutionized the unbiased annotation of gene function, but most screens done so far have been confined to rather simplistic read-outs (usually life/death of the target cells). Combining pooled CRISPR perturbation with single-cell RNA sequencing allows researchers to assess much more complex phenotypes, thus effectively broadening the scope of these single-cell CRISPR screens. At Myllia, we use the CROP-Seq (Perturb-Seq) technology to perturb cells with CRISPR/Cas9 and profile transcriptional outcomes at scale by RNA sequencing at single-cell resolution. Importantly, our technology is applicable across a wide range of cell types including primary immune cells. The latter include primary human T cells or monocyte-derived cells isolated from PBMCs which are of great interest for the discovery of novel targets in immuno-oncology.
CAS9-EXPRESSING CELLS
Every single-cell CRISPR screen starts in a cell line or primary cell that harbors a CRISPR/Cas9 machinery (e.g., Cas9, dCas9-KRAB, or dCas9-VPR).
LENTIVIRAL GUIDE RNA LIBRARY
Cells are infected with a pooled lentiviral single-guide RNA (sgRNA) library.
CRISPR PERTURBATIONS
Following perturbation with Cas9 and a suitable guide RNA, every single cell in the pool will carry a knockout for a different gene.
Single-cell RNA sequencing
The CROP-Seq (Perturb-Seq) technology measures transcriptome responses to CRISPR perturbation. It offers the flexibility and information content of arrayed CRISPR screens at the scale of pooled CRISPR screens, thus providing a synergy of the two widely popular genetic screening paradigms.
Single-cell RNA sequencing
The CROP-Seq (Perturb-Seq) technology measures transcriptome responses to CRISPR perturbation. It offers the flexibility and information content of arrayed CRISPR screens at the scale of pooled CRISPR screens, thus providing a synergy of the two widely popular genetic screening paradigms.
SINGLE CELL LIBRARY PREPARATION
Each single cell is then encapsulated in a lipid droplet together with a barcoded bead. Reverse transcription occurs on the surface of the bead, thus creating a unique transcriptomic fingerprint for each cell.
GUIDE RNA MAPPING
Mapping of the guide RNAs will connect each single-cell transcriptome to the guide RNA perturbation that caused the transcriptomic phenotype.
NGS AND BIOINFORMATIC ANALYSIS
Single-cell RNA sequencing datasets are typically large and complex. We are routinely analyzing these high-content datasets and are providing bioinformatic/computational analyses that are customized to the specific needs of our clients.
Videos about Myllia's single-cell CRISPR screening technology
Myllia at Drug Discovery 2024 – Single-cell CRISPR screens for target discovery
In October, the Myllia team attended ELRIG's Drug Discovery 2024 in London, UK to present our pooled CRISPR screening platform enabling target discovery/validation at single-cell resolution. Watch the full interview with Myllia's Co-Founder and CSO Tilmann Buerckstuemmer.
A genome-scale CROP-seq screen reveals mediators of T-cell signaling
In a 10x Genomics webinar, Tilmann Buerckstuemmer, CSO at Myllia Biotechnology, describes the use of genome-wide CRISPR screens in target discovery for immuno-oncology. Using targeted sequencing of markers of T cell activation, this CRISPR interference screen represents the largest CROP-seq/ Perturb-seq dataset created to date.
Phoenix Award 2022
Myllia Biotechnology wins the Phoenix award 2022 in the "Start-up" category!
CROP-Seq: CRISPR screens at single-cell resolution
Learn how the CROP-Seq technology at Myllia can help to elucidate novel drug targets at single-cell resolution
Primary human T cell CRISPR screening
At Myllia, CRISPR screens are performed in primary human T cells to explore factors of T cell activation, differentiation and exhaustion. Learn more about our CROP-seq technology to boost CAR-T and TCR-T cell potency!
Targeted sequencing
Would you like to know more about targeted sequencing applications? Explore how tailored PCR panels can boost the NGS read-outs of your next CRISPR screens
What’s the difference between CRISPRko and CRISPRi screens?
Learn more about the differences of CRISPRko and CRISPRi screens
About us
Discover the CRISPR screening portfolio at Myllia Biotechnology
How do CRISPR screens work?
Explore how we can use CRISPR screens to support drug target identification
Resources about Myllia's CROP-Seq (Perturb-Seq) screening platform
Design of highly efficient sgRNA libraries for CRISPRn screens
The design of sgRNAs for CRISPRn, CRISPRi and CRISPRa is a crucial factor determining the success of CRISPR screening experiments. Myllia´s proprietary sgRNA design algorithm selects highly active sgRNA sequences for targeting both essential and non-essential genes and appears to be “superior” to other publicly available libraries.
Poster | Design of sgRNA libraries for CRISPRn screens
The design of sgRNAs for CRISPRn, CRISPRi and CRISPRa is a crucial factor determining the success of CRISPR screening experiments. Myllia´s proprietary sgRNA design algorithm selects highly active sgRNA sequences for targeting both essential and non-essential genes and appears to be “superior” to other publicly available libraries.
RESEARCH ARTICLE in Cell Reports, May 2024
Together with Boehringer Ingelheim, Myllia performed a CROP-Seq screen contributing to the publication: "Genetic dependencies associated with transcription factor activities in human cancer cell lines" in Cell Reports, May 2024
CRISPR screens for immuno-oncology (IO) research
CROP-Seq (Perturb-Seq) in primary T cells - Utilize our tailor-made CRISPR screens to characterize your immuno-oncology drug candidates and CAR-T cell products
Next-generation CRISPR screening for drug target discovery
De-risk target discovery and drug development using the best possible validated targets
Video | Primary human T cell CRISPR screening
At Myllia, CRISPR screens are performed in primary human T cells to explore factors of T cell activation, differentiation and exhaustion. Learn more about our CROP-seq technology to boost CAR-T and TCR-T cell potency!
Video | Targeted sequencing
Would you like to know more about targeted sequencing applications? Explore how tailored PCR panels can boost the NGS read-outs of your next CRISPR screens
Video | CROP-Seq: Single-cell CRISPR screening
Learn how the CROP-Seq (Perturb-Seq) technology at Myllia can help to elucidate novel drug targets at single-cell resolution
Poster | Single-cell CRISPR screens in primary human T cells identify regulators of Th2 cell skewing
T helper 2 (Th2) cell differentiation plays a critical role in regulating allergic responses, defense against parasites, and immune homeostasis. In a CROP-Seq experiment with CD4+ T cells, Th2-skewed cells were studied using a sgRNA library targeting 102 genes with a targeted read-out of 300 mRNAs.
Poster | Large-scale single-cell CRISPR screens in primary human T cells
The CROP-seq experiment in pan T-cells involved a targeted single-cell RNA sequencing of 300 mRNAs. At Myllia, we can identify rare subsets, transitional states, and distinct functional profiles that may be masked in bulk analyses, providing a more comprehensive understanding of T cell activation and differentiation.
Poster | A genome-wide CROP-Seq screen reveals mediators of T cell signaling
The first-of-its-kind genome-scale CRISPRi screen was conducted to verify factors involved in TCR signaling pathways. Unravelling these T cell-intrinsic molecular factors could potentially unlock new therapeutic targets and strategies for modulating T cell responses in various immune-related disorders.
Video | CRISPR/Cas9-based screens: CRISPRko vs. CRISPRi
Learn more about the differences of CRISPR/Cas9-based CRISPRko (knockout) and CRISPRi (interference) screens
Video | How do CRISPR screens work?
Explore how we can use CRISPR screens to support drug target identification
Video | About us
Discover the unique CRISPR screening portfolio developed at Myllia Biotechnology
Download Myllia’s company presentation: CRISPR screens for drug target discovery
At Myllia, we use the CROP-Seq technology to perturb cells with CRISPR and profile transcriptional outcomes by RNA sequencing at single-cell resolution.
Poster | A genome-scale PARPi screen for synthetic lethality
At Myllia, we’ve performed a genome-scale CRISPR KO screen in HeLa cells to identify novel or well-known genes that are involved in DNA damage repair and would resemble gene pairs with PARP.
A CROP-Seq screen for modulators of primary Th2 cell polarization
In a CROP-Seq experiment with CD4+ T cells, Th2-skewed cells were studied using a sgRNA library targeting 102 genes with a targeted read-out of 300 mRNAs.
Large-scale CROP-Seq screening in primary human T cells
At Myllia, we can identify rare subsets, transitional states, and distinct functional profiles that may be masked in bulk analyses, providing a more comprehensive understanding of T cell activation and differentiation. The CROP-seq experiment in pan T-cells involved a targeted single-cell RNA sequencing of 300 mRNAs.
CRISPR-ready cancer cell lines for CRISPRn & CRISPRi screens
Browse through our catalogue of CRISPR-ready cancer cell lines for your next tailor-made CRISPR screens
Our Portfolio
At Myllia, pooled CRISPR screens are performed at large scale, and our unique platform involves a broad portfolio of CRISPR/Cas9 technologies
A genome-wide CROP-Seq CRISPRi screen for factors of TCR signaling
At Myllia, the Perturb-seq (CROP-seq) workflow has been adapted to enable genome-scale CRISPRi (CRISPR interference) screens in Jurkat cells at single-cell resolution. The first-of-its-kind genome-scale CRISPRi screen was conducted to verify factors involved in TCR signaling pathways.
A genome-scale PARPi CRISPR KO screen for synthetic lethality
CRISPR KO screen at genome-scale in HeLa cells to identify novel or well-known genes that are involved in DNA damage repair to explore PARPi synthetic lethality gene pairs.
Our Factsheet
Check out Myllia's technology platform enabling drug target discovery and functional genomics at single-cell resolution